Abstract
The phenanthroindolizidine and phenanthroquinolizidine alkaloids, typified by tylophorine and cryptopleurine, are a family of plant-derived small molecules with significant therapeutic potential. The plant extracts have been used in herbal medicine and the isolated compounds have displayed a range of promising therapeutic activity such as antiameobicidal, anti-viral, anti-inflammatory and anti-cancer activity. Despite their therapeutic protential, no compounds in this class have fully passed clinical trials. Drawbacks include low in vivo anti-cancer activity, central nervous system toxicity and low natural availability. A number of biological effects of these compounds, such as protein and nucleic acid synthesis suppression, have been identified, but the specific biomolecular targets have not yet been identified. Significant effort has been expended in the synthesis and structure-activity-relationship (SAR) studies of these compounds with the hope that a new drug will emerge. This review will highlight important contributions to the isolation, synthesis, SAR and mechanism of action of the phenanthroindolizidine and pheanthroquinolizidine alkaloids.
Current Bioactive Compounds
Title: Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy
Volume: 5 Issue: 1
Author(s): Sherry R. Chemler
Affiliation:
Abstract: The phenanthroindolizidine and phenanthroquinolizidine alkaloids, typified by tylophorine and cryptopleurine, are a family of plant-derived small molecules with significant therapeutic potential. The plant extracts have been used in herbal medicine and the isolated compounds have displayed a range of promising therapeutic activity such as antiameobicidal, anti-viral, anti-inflammatory and anti-cancer activity. Despite their therapeutic protential, no compounds in this class have fully passed clinical trials. Drawbacks include low in vivo anti-cancer activity, central nervous system toxicity and low natural availability. A number of biological effects of these compounds, such as protein and nucleic acid synthesis suppression, have been identified, but the specific biomolecular targets have not yet been identified. Significant effort has been expended in the synthesis and structure-activity-relationship (SAR) studies of these compounds with the hope that a new drug will emerge. This review will highlight important contributions to the isolation, synthesis, SAR and mechanism of action of the phenanthroindolizidine and pheanthroquinolizidine alkaloids.
Export Options
About this article
Cite this article as:
Chemler R. Sherry, Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy, Current Bioactive Compounds 2009; 5 (1) . https://dx.doi.org/10.2174/157340709787580928
DOI https://dx.doi.org/10.2174/157340709787580928 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Protein Kinase C-alpha (PKC-α) in Cancer and its Modulation by the Novel PKC-α-Specific Inhibitor Aprinocarsen
Current Pharmaceutical Design Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Dietary Phytochemicals in Chemoprevention of Cancer
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cadmium and Its Epigenetic Effects
Current Medicinal Chemistry Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Insulin Decreases Therapeutic Efficacy in Colon Cancer Cell Line HT29 Via the Activation of the PI3K/Akt Pathway
Current Drug Discovery Technologies Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Players in ADP-ribosylation: Readers and Erasers
Current Protein & Peptide Science <i>Prunella vulgaris</i> L: Critical Pharmacological, Expository Traditional Uses and Extensive Phytochemistry: A Review
Current Drug Discovery Technologies Nanomedicine: A New Frontier in Cancer Therapeutics
Current Drug Delivery Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design Multi-Targeted Agents in Cancer Cell Chemosensitization: What We Learnt from Curcumin Thus Far
Recent Patents on Anti-Cancer Drug Discovery Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Letters in Drug Design & Discovery Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes
Current Drug Targets Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Interaction of Mesalasine (5-ASA) with Translational Initiation Factors eIF4 Partially Explains 5-ASA Anti-Inflammatory and Anti-Neoplastic Activities
Medicinal Chemistry Antioxidant Treatment for Acute Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry